Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) April 29, 2014

GNbAC1, a Humanized Monoclonal Antibody Against The Multiple Sclerosis Associated Retrovirus Envelope Protein, Is Well Tolerated In Patients With Multiple Sclerosis. (P2.217)

Tobias Derfuss, Francois Curtin, Alois Lang, Herve Perron, Ludwig Kappos, Patrice LaLive
First published April 9, 2014,
Tobias Derfuss
4Neurologische Uniklinik Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Curtin
2GeNeuro SA Geneva Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alois Lang
3GeNeuro SA Plan les Ouates Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herve Perron
3GeNeuro SA Plan les Ouates Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludwig Kappos
5Neurology and Department of Biomedicine, University Hospital Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice LaLive
1Geneva Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
GNbAC1, a Humanized Monoclonal Antibody Against The Multiple Sclerosis Associated Retrovirus Envelope Protein, Is Well Tolerated In Patients With Multiple Sclerosis. (P2.217)
Tobias Derfuss, Francois Curtin, Alois Lang, Herve Perron, Ludwig Kappos, Patrice LaLive
Neurology Apr 2014, 82 (10 Supplement) P2.217;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVES: To assess the safety, pharmacokinetics and pharmacodynamics over 1 year of GNbAC1, a monoclonal antibody agonist of the Multiple Sclerosis associated Retrovirus (MSRV) Env protein in multiple sclerosis (MS) patients. BACKGROUND: Human endogenous retrovirus (HERV) genes represent 8% of the human genome. Among HERV genes, the Multiple Sclerosis associated Retrovirus (MSRV) DNA contains copies expressing a protein called Env, which can activate a pro-inflammatory and autoimmune cascade via Toll-Like receptor 4. MSRV-Env expressed in multiple sclerosis (MS) plaques has an inhibitory effect on oligodendrocyte precursor cell differentiation and affects remyelination. GNbAC1, a humanised monoclonal antibody, binds MSRV-Env. Blocking MSRV-Env by GNbAC1 is expected to have a neuroprotective effect in MS. DESIGN: We report the results of Phase II single ascending dose study followed by a 12-month open-label extension to evaluate the safety, pharmacokinetics and pharmacodynamics of GNbAC1 in 10 MS patients. First, in Cohort 1, 5 patients were randomized to receive a single intravenous infusion of 2 mg/kg of GNbAC1 or placebo; in Cohort 2, 5 patients were randomized to receive an intravenous infusion of 6 mg/kg of GNbAC1 or placebo. Then, all patients of Cohorts 1 and 2 pursued treatment with 11 GNbAC1 infusions at 2 mg/kg and 6 mg/kg dose respectively at 4-week intervals. RESULTS: Over the long term, GNbAC1 was well tolerated at both doses. No safety or immunogenicity signals were detected. Pharmacokinetic data confirm a dose linear pharmacokinetics with an elimination half-life of 15-17 days compatible with monthly infusions. Pharmacodynamic and MSRV biomarkers are presented. CONCLUSIONS: The 12-month results confirm the favorable long-term GNbAC1 safety profile in MS patients and the pharmacokinetics allows monthly administration scheme. These results support the launch of a larger Phase II study testing the efficacy and safety of the first monoclonal antibody targeting the MSRV-Env protein.

Disclosure: Dr. Derfuss has nothing to disclose. Dr. Curtin has received personal compensation for activities with GeNeuro. Dr. Lang has received personal compensation for activities with GeNeuro as an employee. Dr. Perron has received personal compensation for activities with Geneuro as an employee. Dr. Kappos has received personal compensation for activities with the University Hospital Basel. Dr. Kappos has received research support from the Swiss MS Society, Swiss National Research Foundation, the European Union, Gianni Rubatto Foundation, Novartis, and Roche Diagnostics Corp. Dr. LaLive has received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals Inc., Teva Neuroscience, Geneuro, and Genzyme Corp. Dr. LaLive has received research support from Biogen Idec, Merck Serono, and Novartis.

Tuesday, April 29 2014, 7:30 am-11:00 am

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (3)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise